All In Biotech

NDA 020479 · Viatris Specialty

Gastrocrom

Cromolyn Sodium · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Feb 13, 2003 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Feb 29, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

7 Phase 3, 4 recruiting

FAERS reports

3,311

1,201 serious, 38 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 26, 2024.

INDICATIONS AND USAGE GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients.

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 29, 1996 Original approval · Type 3 - New Dosage Form
1 products under this application
  • GASTROCROM · CROMOLYN SODIUM 100MG/5ML · CONCENTRATE, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Cromolyn" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,006
  • drug ineffective301
  • fatigue204
  • nausea193
  • headache168
  • off label use164
  • diarrhoea160
  • urticaria147
  • dyspnoea130
  • anaphylactic reaction127
  • pruritus124
  • pain122

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200428
200524
200617
200720
200828
200944
201039
201145
201226
201316
201425
201540
201685
201765
201870
2019104
20201,101
2021139
2022212
2023256
2024317
2025346
2026264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gastrocrom (Cromolyn Sodium)

2024 spending

$1.0M

Beneficiaries

81

291 claims

Per beneficiary

$12,890

$2.21 per unit

View as table
YearSpending
2020$458,010
2021$459,042
2022$539,009
2023$663,437
2024$1,044,112

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 268 on PubMed

Sponsor: Viatris Specialty

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.